CabreraSM, BrightGM, FraneJW, BlethenSL, LeePA: Age of thelarche and menarche in contemporary U.S. females: a cross-sectional analysis. J Pediatr Endocrinol Metab, 27: 47–51, 2014.
2.
CacciaS: Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs, 15:217–233, 2013.
3.
CorrellCU, LeuchtS, KaneJM: Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry, 20:195–201, 2008.
4.
DunbarF, KusumakarV, DanemanD, SchulzM: Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry, 161:918–920, 2004.
5.
GreenspanSL, OppenheimDS, KlibanskiA: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med, 110:526–531, 1989.
6.
HowlettTA, WassJA, GrossmanA, PlowmanPN, CharlesworthM, TouzelR: Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: Response to medical therapy. Clin Endocrinol (Oxf), 30:131–140, 1989.
7.
KawanoY, KamihigashiS, NakamuraS, MiyakawaI: Delayed puberty associated with hyperprolactinemia caused by a pituitary microadenoma. Arch Gynecol Obstet, 264:90–92, 2000.
8.
PattonML, WoolfPD: Hyperprolactinemia and delayed puberty: A report of three cases and their response to therapy. Pediatrics, 71:572–575, 1983.
9.
ReyesM, CroonenberghsJ, AugustynsI, EerdekensM: Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol, 16:260–272, 2006.
10.
RokeY, van HartenPN, BootAM, BuitelaarJK: Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol, 19:403–414, 2009.
11.
RokeY, BuitelaarJK, BootAM, TenbackD, van HartenPN: Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder treated with risperidone. J Child Adolesc Psychopharmacol, 22:432–439, 2012.
12.
SackJ, FriedmanE, TadmorR, SaharA, KatznelsonD: Growth and puberty arrest due to prolactinoma. Acta Paediatr Scand, 73:863–867, 1984.
13.
SikichL, HamerRM, BashfordRA, SheitmanBB, LiebermanJA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29:133–145, 2004.
14.
SzarfmanA, TonningJM, LevineJG, DoraiswamyPM: Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. Presented in part as a poster presentation at the 6th International Bipolar Disorders Conference, Pittsburgh, Pennsylvania, June 16–18, 2005.
15.
TorenP, RatnerS, LaorN, WeizmanA: Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety, 27:1135–1156, 2004.
